NFKB1 and hepatocellular carcinoma: Anxa2, acting as an NF-κB co-activator in hepatocellular carcinoma and pancreatic cancer [28,29], was first identified bound to p50 subunit of NF-κB in breast cancer cells (Figure 1A,B).